Clinical Trial Update: A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 study of Ontorpacept (TTI-621) alone or with doxorubicin in leiomyosarcoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• Ontorpacept (TTI-621)

Snippet

Sponsor: Pfizer | Conditions: Leiomyosarcoma | Phase 2 | Status: TERMINATED | Results posted: 2024-12-11